Dual PDGF/VEGF antagonists

US11155610B2 · kind B2 · utility

Assignee

• KODIAK SCIENCES INC. · US

Inventors

• Daniel Victor Perlroth · Palo Alto, US
• Stephen A. Charles · Ravenna, US
• James Aggen · Westwood, US
• Didier Benoit · San Jose, US
• Wayne To · San Mateo, US
• Lidia Mosyak · Newton, US
• Laura Lin · Weston, US
• Justin Cohen · Quincy, US
• Tetsuya Ishino · Boston, US
• William Somers · Cambridge, US

Key dates

• Filing date: Nov 21, 2017
• Grant date: Oct 26, 2021
• Expiry date: Nov 21, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.